[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ipf\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ipf":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,52,79,101,121,147,176,203,227,248],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":36,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100565589","p4o2-ild-extension-100565589",false,"NCT06644144","P4O2 ILD Extension","Early Identification of Progressive Pulmonary Fibrosis, Precision Medicine for More Oxygen - ILD Extension.","P4O2-ILD","Inclusion Criteria:\n\n* Diagnosis of (1) idiopathic pulmonary fibrosis (IPF), familial pulmonary fibrosis (FPF), (2) other fibrotic ILDs (fILD), including fibrotic hypersensitivity pneumonitis (fHP), idiopathic non-specific interstitial pneumonia (iNSIP), connective tissue disease (CTD)-ILD, and unclassifiable ILD (uILD); or (3) interstitial lung abnormalities (ILA).\n* Meeting all the following criteria during the screening period:\n\n  1. FVC ≥45% predicted.\n  2. FEV1\u002FFVC ≥0.7.\n  3. DLco corrected for Hb ≥40% predicted.\n* Able to provide written informed consent as approved by the independent ethics committee.\n* Able to undergo a CT scan and perform PFT.\n* Age \\> 18 years and \\< 80 years.\n* Understanding of the Dutch or English language.\n\nExclusion Criteria:\n\n* Combined pulmonary fibrosis and emphysema (CPFE) diagnosis\n* Chronic obstructive lung disease (COPD) with an FEV1\u002FFVC \\<70%.\n* Uncontrolled severe asthma.\n* Active malignancy, except for squamous cell carcinoma of the skin, low-risk breast cancer, and low-risk prostate cancer.\n* Pregnancy or lactating.","ALL","18 Years","80 Years",{"count":21,"type":22},450,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to identify early biomarkers that can predict the development of progressive pulmonary fibrosis (PPF) in participants with interstitial lung diseases (ILDs). The participant population includes adults diagnosed with idiopathic pulmonary fibrosis (IPF), familial pulmonary fibrosis (FPF), other fibrotic ILDs, and interstitial lung abnormalities (ILA).\n\nThe main questions it aims to answer are:\n\n* What biomarkers and risk factors are linked to fibrosis progression or can predict rapid worsening and sudden flare-ups in IPF and FPF patients?\n* What biomarkers and risk factors can predict the development of a PPF phenotype in different types of ILD?\n* What biomarkers and risk factors can help identify ILA patients who may develop significant ILD?\n* What biomarkers and risk factors can predict how well ILD patients will respond to treatment?\n\nResearchers will compare the outcomes between participants diagnosed with IPF\u002FFPF, other fibrotic ILDs, and ILA to see if early detection biomarkers differ among these groups.\n\nParticipants will:\n\n* Undergo blood sampling.\n* Perform lung function tests.\n* Have CT scans.\n* Perform breath analysis\n* Participate in exposome and microbiome analyses.\n* Complete questionnaires.\n* A subgroup of participants will be offered bronchoscopy.",[26,27,28,29,30,31,32,33,34,35],"Interstitial Lung Disease","Pulmonary Fibrosis","Interstitial Lung Fibrosis","IPF","Pulmonary Fibrosis, Idiopathic","Pulmonary Fibrosis Idiopathic Familial","Chronic Hypersensitivity Pneumonitis","Unclassifiable ILD","Idiopathic NSIP","CTD-ILD",[26,37,38],"Interstitial Lung Abnormalities","Progressive Pulmonary Fibrosis","RECRUITING","2026-05-05",{"date":42,"type":43},"2026-05-11","ACTUAL",{"date":45,"type":43},"2024-11-01",{"date":47,"type":22},"2031-10-01",{"name":49,"class":50},"Amsterdam UMC, location VUmc","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":17,"minAge":18,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":51},"100633593","phase-1-a-clinical-study-to-evaluate-the-safety-tolerability-and-pharmacokinetic-characteristics-of-rc010-inhalation-powder-in-healthy-participants-100633593","NCT07528703","A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of RC010 Inhalation Powder in Healthy Participants","A Phase Ia Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of RC010 Inhalation Powder in Healthy Chinese Participants","Inclusion Criteria:\n\n1. Be able to communicate well with the researchers, fully understand the objectives and requirements of this trial, voluntarily participate in the clinical trial and sign a written informed consent form;\n2. Aged between 18 and 55 years inclusive, of both genders;\n3. Have a body mass index (BMI) between 19.0 kg\u002Fm² and 28.0 kg\u002Fm² inclusive, and a body weight of ≥ 50.0 kg for males or ≥ 45.0 kg for females;\n4. Have no plans for childbearing, sperm donation or egg donation from the time of voluntarily signing the informed consent form until 90 days after the last dose, and voluntarily adopt medically approved contraceptive measures (including their partners, see Appendix 1 for details).\n\nExclusion Criteria:\n\n1. Received clinical trial medication or participated in other medical research activities within 3 months prior to screening, and is deemed unsuitable for study enrollment by the investigator.\n2. Has a history of or currently suffers from clinically unstable diseases\u002Fabnormalities of the cardiovascular, respiratory, endocrine, metabolic, renal, hepatic, gastrointestinal, dermatological, infectious, hematological, nervous, or neuropsychiatric systems, which the investigator judges to interfere with study conduct.\n3. Has a history of glaucoma, functional constipation, benign prostatic hyperplasia, urinary tract obstruction, or similar conditions.\n4. Has a history of severe oral\u002Fmaxillofacial deformities, or presents with oral candidiasis, ulcers, or other mucosal lesions at screening that may affect oral inhalation administration.\n5. Has a past or current history of bleeding risk-increasing diseases (e.g., acute gastritis, active bleeding peptic ulcers), clinically significant thrombocytopenia\u002Fanemia (Hb \\\u003C 80 g\u002FL and\u002For PLT \\\u003C 100×10⁹\u002FL), active pathological bleeding, or intracranial hemorrhage history.\n6. Suffered from lower respiratory tract infection, or upper respiratory tract infection requiring antibiotic therapy, within 6 weeks prior to screening\u002Fenrollment.\n7. Has a history of chronic obstructive pulmonary disease (COPD) or other respiratory diseases, including but not limited to tuberculosis infection, α-1 antitrypsin deficiency, cystic fibrosis, symptomatic asthma, bronchiectasis, sarcoidosis, pulmonary fibrosis, pulmonary arterial hypertension, pulmonary edema, or interstitial lung disease.\n8. Received any live vaccine (excluding influenza vaccine) within 30 days prior to screening, or plans to receive vaccines during the study period.\n9. Has a history of drug allergies, specific allergic conditions (e.g., asthma, urticaria, eczema), is an atopic individual (allergic to ≥2 types of drugs\u002Ffoods\u002Fpollen), or has a known allergy to any component of RC010 Inhalation Powder.\n10. Lost blood or donated blood \\> 400 mL within 3 months prior to screening (excluding female menstrual blood loss), or intends to donate blood during the study or within 1 month post-study.\n11. Underwent surgery within 1 month prior to screening, or plans to undergo surgery during the study period.\n12. Excessively consumed tea, coffee, or caffeinated beverages (average ≥ 8 cups\u002Fday, 250 mL\u002Fcup) within 6 months prior to screening.\n13. Ingested caffeine\u002Fxanthine-containing products (e.g., coffee, tea, cola, chocolate), poppy seed-containing foods, or CYP2C8\u002FCYP3A4-affecting substances (e.g., limes, grapefruit\u002Fjuice, pomelos) within 48 hours prior to investigational product administration.\n14. Used hepatic drug-metabolizing enzyme inhibitors\u002Finducers within 28 days prior to screening; or used prescription drugs, over-the-counter drugs, Chinese herbal medicines, or health supplements within 14 days prior to screening. For long half-life drugs, the washout period shall be at least 5 times the drug half-life.\n15. Has special dietary requirements and cannot comply with the unified study diet.\n16. Has venous blood collection difficulties, or a history of needle phobia\u002Fhematophobia.\n17. Is a heavy smoker (smoking ≥ 5 cigarettes\u002Fday within 3 months prior to the first dose), cannot comply with smoking prohibition during the study, or has a positive smoking test result.\n18. Has a history of regular alcohol consumption within 6 months prior to screening (women \\> 14 standard units\u002Fweek, men \\> 21 standard units\u002Fweek; 1 unit = 14g alcohol), cannot abstain from alcohol during the study, or has a positive breath alcohol test result.\n19. Has a history of drug abuse, or has a positive drug abuse screening result (including benzodiazepines, methamphetamine, cocaine, morphine, ketamine, tetrahydrocannabinol carboxylic acid).\n20. Has clinically significant abnormal findings in screening physical examination, vital signs, laboratory tests (blood\u002Furine\u002Fstool routine, biochemistry, coagulation, thyroid function, etc.), abdominal B-ultrasound, or chest X-ray, as judged by the investigator.\n21. Has positive screening results for HBsAg, anti-HCV, TPPA, or HIV-Ag\u002FAb.\n22. Has screening pulmonary function test results showing FEV₁\u002Fpredicted value ≤ 80%, FVC ≤ 80% of predicted value, or other clinically significant abnormalities.\n23. Is a pregnant\u002Flactating woman, or has a positive screening blood pregnancy test result.\n24. Has clinically significant abnormal 12-lead ECG findings at screening (e.g., bradycardia\u002Ftachycardia, QTcF ≥ 450 ms \\[male\\]\u002F≥ 470 ms \\[female\\], arrhythmia), as judged by the investigator.\n25. Has screening serum potassium concentration \\\u003C 3.5 mmol\u002FL.\n26. Is unwilling\u002Funable to correctly use the inhaler for investigational product administration, or fails inhalation training.\n27. Is deemed unsuitable for study participation due to other circumstances judged by the investigator.",true,"55 Years",{"count":62,"type":22},42,"INTERVENTIONAL",[65],"PHASE1","This is a Phase 1A, first in human, randomized, double-blinded, placebo-controlled, dose escalation study of RC010 in healthy adult volunteers. RC010 is a small-molecule drug , being developed as a novel therapeutic treatment for patients with Idiopathic Pulmonary fibrosis (IPF). This study aims to evaluate the safety, tolerability and pharmacokinetics of RC010 after Single ascending doses .",[29],"NOT_YET_RECRUITING","2026-04-07",{"date":71,"type":43},"2026-04-14",{"date":73,"type":22},"2026-04",{"date":75,"type":22},"2027-12",{"name":77,"class":78},"Nanjing Reju Therapeutics Co., Ltd","INDUSTRY",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":63,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":4},"100632852","phase-3-a-multicenter-randomized-double-blind-placebo-controlled-phase-iii-study-to-evaluate-the-efficacy-and-safety-of-hsk44459-tablets-in-patients-with-idiopathic-pulmonary-fibrosis-100632852","NCT07519070","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis","Inclusion Criteria:\n\n1. Age ≥40 years, regardless of gender;\n2. Diagnosis of IPF confirmed prior to or during screening per the 2022 ATS\u002FERS\u002FJRS\u002FALAT guidelines (Appendix 1);\n3. Patients must meet one of the following criteria:\n\n   1. No treatment with nintedanib or pirfenidone for at least 8 weeks prior to screening (e.g., treatment-naïve or discontinued therapy), with no plans to initiate or resume antifibrotic treatment;\n   2. On a stable regimen of nintedanib or pirfenidone for at least 12 weeks prior to screening, without combination therapy with both drugs. \\[Stable therapy is defined as maintaining a constant dosage with tolerable drug-specific adverse events\\];\n4. Percentage predicted forced vital capacity (FVCpp) ≥45% at screening;\n5. Percentage predicted diffusing capacity of the lungs for carbon monoxide (DLCOpp) ≥25% and \\\u003C90% at screening \\[\\*hemoglobin (Hb)-adjusted\\];\n6. Willing to participate and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n1. Clinically significant airway obstruction during screening \\[pre-bronchodilator forced expiratory volume in 1 second\u002Fforced vital capacity (FEV1\u002FFVC) \\\u003C0.7\\];\n2. Other clinically significant pulmonary abnormalities per investigator judgment (exceptions: conditions requiring no treatment during the trial, e.g., asymptomatic pulmonary nodules, emphysema);\n3. Acute IPF exacerbation within 3 months before screening and\u002For during screening;\n4. Receiving immunomodulators (excluding oral corticosteroids) for respiratory conditions, or prednisone \\>15 mg\u002Fday (or equivalent);\n5. History of vasculitis;\n6. Any suicidal behavior within 2 years before screening (actual attempt, interrupted attempt, aborted attempt, or preparatory acts\u002Fbehaviors);\n7. Type 4 or 5 suicidal ideation per Columbia-Suicide Severity Rating Scale (C-SSRS) within 3 months before\u002Fduring screening (active suicidal thoughts with method\u002Fintent but no plan, or with method\u002Fintent\u002Fplan);\n8. Respiratory infection requiring antibiotics or other infections requiring treatment within 4 weeks before\u002Fduring screening;\n9. Major surgery within 3 months before screening or planned during the study (investigator-assessed; lung transplant listing excluded);\n10. Malignancy within 5 years before screening (except treated basal cell carcinoma, squamous cell carcinoma in situ, or cervical carcinoma in situ);\n11. Blood pressure ≥160\u002F100 mmHg at screening;\n12. Unstable\u002Fworsening cardiovascular\u002Fcerebrovascular disease within 6 months before screening (e.g., unstable angina, myocardial infarction, heart failure, thromboembolic events including stroke\u002FTIA);\n13. Aspartate transaminase (AST) or alanine transaminase (ALT) \\>2.5×ULN or total bilirubin \\>1.5×ULN at screening;\n14. Estimated glomerular filtration rate (eGFR) ≤30 mL\u002Fmin\u002F1.73 m² at screening;\n15. Gastrointestinal surgery\u002Fdisease affecting pharmacokinetics (PK) (except appendectomy\u002Fhernia repair);\n16. Active hepatitis B \\[HBsAg-positive with HBV-DNA above ULN\\], hepatitis C antibody-positive, syphilis (anti-TP-positive with TRUST above ULN), or HIV infection (anti-HIV-positive) at screening;\n17. Current treated liver disease with Child-Pugh A\u002FB\u002FC impairment at screening;\n18. Substance abuse, drug use, or excessive alcohol intake (\\>2 units\u002Fday; 1 unit=360 mL beer \\[5%\\], 45 mL spirits \\[40%\\], or 150 mL wine) within 3 months before screening;\n19. Tobacco\u002Fnicotine product use within 3 months before screening or unwillingness to abstain during the study;\n20. Previous HSK44459 use or PDE1\u002F3\u002F4\u002F10\u002Fnon-selective PDE inhibitor treatment (excluding HSK44459, e.g., apremilast, roflumilast, ibudilast) within 8 weeks before screening;\n21. Use of strong CYP3A4 inhibitors\u002Finducers within 14 days or 5 half-lives (whichever longer) before first dose, or anticipated need during the study;\n22. History of severe drug allergy or hypersensitivity to investigational product\u002Fexcipients;\n23. Participation in other clinical trials (receiving investigational drug\u002Fplacebo) within 1 month before screening;\n24. Pregnancy\u002Flactation; participants of childbearing potential unwilling to use contraception during and for 3 months post-study (including male participants);\n25. Any other investigator-determined factors making participation unsuitable.","40 Years",{"count":87,"type":22},420,[89],"PHASE3","This study aims to evaluate the efficacy and safety of HSK44459 tablets in patients with idiopathic pulmonary fibrosis (IPF).",[29],"2026-03-31",{"date":94,"type":43},"2026-04-09",{"date":96,"type":22},"2026-04-05",{"date":98,"type":22},"2028-12-30",{"name":100,"class":78},"Haisco Pharmaceutical Group Co., Ltd.",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":59,"sex":17,"minAge":18,"maxAge":60,"enrollmentInfo":108,"targetDuration":4,"studyType":63,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":117,"leadSponsor":119,"locationsCount":51},"100630850","phase-1-a-phase-study-of-hw252001-in-healthy-subjects-100630850","NCT07493031","A PhaseⅠ Study of HW252001 in Healthy Subjects","A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HW252001 Tablets After Single and Multiple Dosing in Healthy Subjects","Inclusion Criteria:\n\n* The participant must sign informed consent prior to the trial, understand the trial's content, procedures, and potential adverse reactions, and be able to complete the study in accordance with the trial protocol requirements.\n* Healthy male or female subjects, aged ≥18 and ≤55 years on the day of signing the informed consent form.\n* During the screening period, male participants must weigh ≥50 kg, and female participants must weigh ≥45 kg. Body Mass Index (BMI) = weight (kg) \u002F height² (m²), and must be within the range of 19 kg\u002Fm² to 26 kg\u002Fm².\n\nExclusion Criteria:\n\n* Subjects with a history of malignant tumors (except for cancer with confirmed cure or remission for ≥5 years, radically resected basal or squamous cell skin cancer, carcinoma in situ of the cervix, and resected colonic polyps);\n* Subjects judged by the investigator to have any condition or disorder that may affect the absorption, metabolism, and\u002For excretion of the study drug.\n* Subjects with severe infection, severe trauma, or major surgery within 3 months prior to the screening or baseline period; or those with planned surgery during the trial period.\n* Subjects with a history of blood donation or significant blood loss (≥400 mL) within 8 weeks prior to the screening or baseline period, or those who have received a blood transfusion within 4 weeks prior to the screening or baseline period; or those who intend to donate blood during the trial period.\n* Subjects with a positive result for any of the following at screening: Hepatitis B virus surface antigen (HBsAg), human immunodeficiency virus (HIV) antibody, Treponema pallidum antibody, or hepatitis C virus antibody.\n* Subjects with a history of heavy smoking (averaging \\>5 cigarettes per day) within 4 weeks prior to screening or baseline, or those unable to discontinue the use of any tobacco products during the trial period.\n* Subjects with an average daily alcohol intake exceeding 15g (equivalent to 450 mL of beer, 150 mL of wine, or approximately 50 mL of low-alcohol liquor) within 4 weeks prior to the screening or baseline period; or those unable to abstain from alcohol during the trial; or those with a positive breath alcohol test at baseline.\n* Subjects with a history of drug abuse or drug dependency prior to screening or baseline; or those with a positive urine drug test at baseline.\n* Subjects who consumed excessive amounts of tea, coffee, or caffeine-containing beverages (averaging more than 8 cups per day, 250 mL per cup) within 48 hours prior to the first dose.\n* Subjects with specific dietary requirements who are unable to comply with the unified diet.\n* Subjects allergic to any component of the study drug; or those with a history of allergic diseases or a predisposition to allergies.\n* Subjects with dysphagia, difficulty with venous blood collection, or physical conditions that cannot tolerate intensive blood sampling.\n* Subjects judged by the investigator as unsuitable to participate in this trial for any other reason.",{"count":109,"type":22},98,[65],"This is a phase 1, randomized, double-blind, placebo-controlled, Single\u002Fmultiple ascending doses (SAD\u002FMAD) study of HW252001 in healthy subjects. This study aims to evaluate the safety, tolerability, pharmacokinetics and Pharmacodynamics of HW252001.",[29],"2026-03-24",{"date":115,"type":43},"2026-03-27",{"date":92,"type":22},{"date":118,"type":22},"2026-12-11",{"name":120,"class":78},"Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":59,"sex":17,"minAge":18,"maxAge":60,"enrollmentInfo":128,"targetDuration":4,"studyType":63,"phases":130,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":51},"100627404","phase-1-a-phase-ia-clinical-trial-of-hw241045-100627404","NCT07448194","A Phase Ia Clinical Trial of HW241045","A Phase Ia Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of HW241045 Tablets Following a Single Dose in Healthy Subjects: A Single-center, Randomized, Double-blind, Placebo-controlled Study","Key Inclusion Criteria:\n\n* The subjects have been fully informed of the trial's purpose, nature, methodology, and potential adverse reactions. They voluntarily participate in the trial and sign the informed consent form prior to the initiation of any study procedures;\n* Healthy male and female subjects aged 18 to 55 years;\n* Female subjects must have a body weight of ≥ 45 kg and male subjects ≥ 50 kg, with a body mass index (BMI) ranging from 19 to 26 kg\u002Fm².\n\nKey Exclusion Criteria:\n\n* Subjects with a history of or current severe clinical disease involving any of the following systems: circulatory, endocrine, nervous, digestive, respiratory, hematological, immune, mental, or metabolic systems; or subjects with any other disease that the investigator judges may interfere with the study results;\n* Subjects with a history of severe trauma or major surgery within 3 months prior to screening; or subjects planning to undergo surgery during the trial period or within two weeks after study completion;\n* Subjects with a history of gastrointestinal, hepatic, or renal diseases that affect drug absorption or metabolism; or those with conditions known or suspected to interfere with drug ingestion, transport, absorption, distribution, metabolism, or excretion;\n* Subjects with clinically significant abnormalities in any screening test results as judged by the investigator;\n* Subjects with a history of drug or food allergy, allergic disorders, or atopic diathesis; or those with confirmed hypersensitivity to any component of the investigational drug;\n* Subjects with difficult venous blood collection, or whose physical condition cannot tolerate intensive blood sampling;\n* Not suitable for this study as judged by the investigator.",{"count":129,"type":22},56,[65],"This is a Phase Ia, randomized, double-blind, placebo-controlled study to assess the safety, tolerability and pharmacokinetic (PK) of HW241045 in healthy subjects following a single ascending dose.",[133,29],"Healthy Volunteers",[135,136,137,138],"HW241045","healthy volunteers","Safety","Pharmacokinetics","2026-03-03",{"date":141,"type":43},"2026-03-04",{"date":143,"type":43},"2025-11-24",{"date":145,"type":22},"2026-06",{"name":120,"class":78},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":63,"phases":157,"briefSummary":159,"conditions":160,"keywords":161,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":51},"100453874","telerehabilitation-in-patients-with-idiopathic-pulmonary-fibrosis-100453874","NCT05190211","Telerehabilitation in Patients With Idiopathic Pulmonary Fibrosis","The Effectiveness of Synchronized Online and Video-based Exercise Programs in Patients With Idiopathic Pulmonary Fibrosis","Inclusion Criteria:\n\n* Being between the ages of 18-75\n* Having a diagnosis of IPF disease diagnosed according to the following clinical diagnostic criteria according to the American Thoracic and European Respiratory Societies (ATS-ERS)\n* Presence of dyspnea on exertion\n* Stable clinical state at the time of admission without infection or exacerbation in the previous 4 weeks\n\nExclusion Criteria:\n\n* Patients with severe comorbid diseases, unstable coronary artery disease, collagen vascular diseases and needing high flow oxygen therapy (˃ 3-4 L \\\\min).\n* A history of effort-related syncope or any comorbidity (such as severe orthopedic or neurological deficits or unstable heart disease) that precludes exercise training.\n* Participation in a pulmonary rehabilitation program within the past 12 months.","75 Years",{"count":156,"type":22},44,[158],"NA","It is to determine the effectiveness of different telerehabilitation exercise programs received to 2 groups randomly formed in idiopathic pulmonary fibrosis (IPF) patients. The cases meeting the inclusion criteria will be randomized and divided into two groups, the groups will be named as Telerehabilitation Exercise Group (TGr) and Video Group (VGr).",[29],[29,162,163,164,165,166],"telerehabilitation","videobased rehabilitation","exercise","physical therapy","pulmonary rehabilitation","2025-11-20",{"date":169,"type":43},"2025-11-21",{"date":171,"type":43},"2021-11-26",{"date":173,"type":22},"2026-08-01",{"name":175,"class":50},"Istanbul Medipol University Hospital",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":63,"phases":185,"briefSummary":187,"conditions":188,"keywords":191,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":202},"100573564","phase-2-sb17170-phase-2-trial-in-ipf-patients-100573564","NCT06747923","SB17170 Phase 2 Trial in IPF Patients","A Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter, Exploratory Phase IIa Clinical Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Properties of SB17170 in Idiopathic Pulmonary Fibrosis (IPF) Patients.","Inclusion Criteria:\n\n1. Adult male\u002Ffemale 40 years or older at the time of obtaining informed consent\n2. Patients diagnosed with idiopathic pulmonary fibrosis who meet the following criteria:\n\n   * Patients with idiopathic pulmonary fibrosis who are confirmed by chest High-Resolution Computed Tomography (HRCT) scan\n   * Patients with Usual Interstitial Pneumonia (UIP) or probable UIP HRCT pattern consistent with a diagnosis of idiopathic pulmonary fibrosis confirmed through central reading of chest HRCT before the baseline visit\n3. Patients with a history of idiopathic pulmonary fibrosis treatment who meet the defined criteria\n4. Patients with Forced Vital Capacity (FVC) ≥ 45% of the normal predicted value at the screening visit\n5. Patients meeting pulmonary function test criteria at the screening visit\n6. Patients who have received the explanation of this clinical trial and voluntarily agreed and signed the informed consent form\n\nExclusion Criteria:\n\n1. When there is a primary disease showing UIP patterns (rheumatoid arthritis-related interstitial lung disease, connective tissue disease-related interstitial lung disease, etc.) and\u002For other clinically significant lung abnormalities\n2. Patients with confirmed acute exacerbation of IPF within 6 months prior to screening and\u002For during the screening period\n3. Patients with lower respiratory tract infections requiring antibiotic treatment\n4. Patients who underwent major surgery within 3 months before screening or have major surgery planned during the clinical trial\n5. Patients with a history of malignancy or documented evidence of active or suspected malignancy within 5 years prior to screening\n6. Patients with evidence of active infection\n7. Patients with the following cardiovascular and cerebrovascular diseases at the time of screening:\n\n   * Severe hypertension within 3 months\n   * Myocardial infarction or unstable angina within 6 months\n   * History of thrombotic events within 6 months\n   * Diagnosis of heart failure within 6 months\n8. Patients with pulmonary hypertension\n9. Patients who are unable to take drugs orally or have a history of major gastrointestinal surgery or pathological findings that may affect the absorption of the investigational product\n10. Patients with Human Immunodeficiency Virus (HIV) infection or active hepatitis B or C",{"count":184,"type":22},30,[186],"PHASE2","This clinical trial is a 2:2:1 randomized, double-blind, placebo-controlled, parallel group, exploratory phase II trial. The main objective of this trial is to compare and evaluate change in FVC compared to placebo by administering SB17170 to moderate to severe patients with IPF. This clinical trial treatment involves administering SB17170 or placebo for 12 weeks.",[29,189,190],"Idiopathic Pulmonary Fibrosis","Idiopathic Pulmonary Fibrosis (IPF)",[192],"HMGB1","2025-11-17",{"date":195,"type":43},"2025-11-19",{"date":197,"type":43},"2025-01-27",{"date":199,"type":22},"2026-10-31",{"name":201,"class":78},"SPARK Biopharma",5,{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":212,"conditions":213,"keywords":214,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":51},"100450600","turkish-validity-and-reliability-of-sgrq-i-100450600","NCT05147597","Turkish Validity and Reliability of SGRQ-I","Turkish Validity and Reliability of the Saint George Respiratory Questionnaire Idiopathic Pulmonary Fibrosis Version (SGRQ-I)","Inclusion Criteria:\n\n* Be over 18 years old\n* Having a Diagnosis of Idiopathic Pulmonary Fibrosis\n* To be literate in Turkish\n\nExclusion Criteria:\n\n* Exacerbation or exacerbation in the last 6 weeks\n* Presence of comorbidities affecting ambulation\n* Cognitive impairment",{"count":211,"type":22},180,"The Saint George Respiratory Questionnaire (SGRQ) questionnaire is a frequently used questionnaire in the respiratory patient group, and the Turkish version of this questionnaire, which was created for use in idiopathic pulmonary fibrosis patients, is not available. There is no commonly used quality of life questionnaire in patients with idiopathic pulmonary fibrosis. The aim of the study is to translate and validate the SGRQ idiopathic pulmonary fibrosis version of questionnaire into Turkish.",[29],[215,216,29,217],"SGRQ","SGRQ-I","Quality of life","2025-04-29",{"date":220,"type":43},"2025-05-01",{"date":222,"type":43},"2022-01-09",{"date":224,"type":22},"2026-01-01",{"name":226,"class":50},"Saglik Bilimleri Universitesi",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":51},"100317876","the-role-of-laryngopharyngeal-reflux-in-ipf-100317876","NCT03418350","The Role of Laryngopharyngeal Reflux in IPF","Inclusion Criteria:\n\n* Diagnosis of IPF\n* Age 40-95\n* Able to read, speak, and understand English\n* If subjects are currently taking medication for reflux or GERD, they much be on a stable does for at least 4 weeks prior to consent.\n\nExclusion Criteria:\n\n* Patients who do not meet all inclusion criteria\n* Pregnant females","95 Years",{"count":235,"type":22},60,"The primary objective of this study is to show that the Supraglottic Index (SGI) is an easily-collected index that accurately identifies the presence and severity of laryngopharyngeal reflux (LPF) in idiopathic pulmonary fibrosis (IPF).",[29,238],"Reflux","2024-11-12",{"date":241,"type":43},"2024-11-14",{"date":243,"type":43},"2018-08-01",{"date":245,"type":22},"2026-12",{"name":247,"class":50},"National Jewish Health",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":17,"minAge":255,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":270,"locationsCount":51},"100454099","sleep-hygiene-sarcopenia-and-cognitive-function-in-respiratory-disease-100454099","NCT05193136","Sleep Hygiene, Sarcopenia, and Cognitive Function in Respiratory Disease","Examination of the Relationship Between Sleep Hygiene, Sarcopenia, and Cognitive Function in Patients With Chronic Obstructive Pulmonary Disease or Idiopathic Pulmonary Fibrosis","Inclusion Criteria:\n\n* Subjects with COPD or IPF.\n\nExclusion Criteria:\n\n* Subjects who have been hospitalized for exacerbation of respiratory failure within 1 month of study participation\n* Subjects who have already been diagnosed with sarcopenia or cognitive dysfunction\n* Subjects receiving long-term oxygen therapy (LTOT) or non-invasive ventilation therapy (NIV)\n* Subjects with obstructive sleep apnea who are indicated for continuous positive airway pressure (CPAP)\n* Subjects with severe complications such as cardiovascular disease, liver disease, renal disease, malignancy, and neurological disease.","20 Years",{"count":257,"type":22},120,"We aim to clarify the relationship between sleep hygiene and the onset of sarcopenia or cognitive dysfunction using sleep time, arousal, and sleep quality as indicators in COPD or IPF patients, and clarify the effects of sleep hygiene on disease progression and life prognosis.",[260,261,262,263,29],"Sleep Hygiene","Sarcopenia","Cognitive Function","COPD","2023-03-25",{"date":266,"type":43},"2023-03-28",{"date":268,"type":43},"2021-12-10",{"date":75,"type":22},{"name":271,"class":50},"National Hospital Organization Minami Kyoto Hospital"]